AbstractEight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas.
Figures & Tables
Vol. 90 No. 11 (2005): November, 2005 : Comparative Studies
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com